ClinicalTrials.gg
RecruitingNCT07136207Updated Aug 22, 2025

Development and Validation of Delirium Recognition Using Computer Vision in Neuro-critical Patients

An observational study in Delirium and Artificial Intelligence (AI), sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Beijing Tiantan Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Delirium with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Delirium · China.

Planned enrollment
4th of 30
1,000 · median 249
Started
2025
with 7 others
Observational
30 of 96
12 open now
Primary completion
2025-12
later than 10 of 29 live
Registered
87th of 96
by date
Lead sponsor
4 of 96
Beijing Tiantan Hospital

Among the 96 studies in Delirium with a site in China, this one is the 4th largest by planned enrollment of the 30 observational ones that give a count, is one of 8 that started in 2025, is one of 30 observational ones, reaches primary completion later than 10 of the 29 other live ones, and was the 87th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

29 of the 96 studies in Delirium with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Delirium with a site in China, or all of them as a file.
02

Study summary

This research project employs machine learning algorithms integrated with computer vision, image processing, and pattern recognition technologies to perform digital analysis of facial expression behaviors in neurocritical care patients with delirium. By constructing multidimensional high-level features of delirium, the investigators have established a classification model based on behavioral. The primary objective of this study is to address the critical challenge of achieving precise and efficient delirium diagnosis in neurologically critically ill patients through automated facial expression behavior recognition.

Read the detailed description

This study is a prospective cohort study approved by the Ethics Committee of Beijing Tiantan Hospital. It aims to support the accurate and efficient diagnosis of delirium in neurocritical patients through a facial expression recognition system. A mobile application was developed for this study, collaboratively designed by senior clinicians and engineers from the Institute of Computing Technology, Chinese Academy of Sciences. The application is based on a stimulus paradigm designed using CAM-ICU (Confusion Assessment Method for the Intensive Care Unit) questions to record dynamic facial videos of neurocritical patients following delirium evaluation based on the DSM-V criteria.

Patients were assessed for delirium and facial expression behavior data were collected twice daily during ICU admission, in two time slots: 8:00-10:00 AM and 8:00-10:00 PM, following the study's inclusion and exclusion criteria. A trained and experienced specialist used the gold standard DSM-V to diagnose delirium. Within five minutes after completing the assessment, dynamic facial behavior video data were collected to prepare images for subsequent model development.

Various image preprocessing and data augmentation techniques were employed to prepare the images for the VGG16 model. These techniques are standard for running convolutional neural network (CNN) models. Using the "preprocess_input"function from the Keras VGGFace module, the investigators standardized image color and size to ensure that each image met the expected input requirements for model training. For data augmentation, the investigators applied TensorFlow's "ImageDataGenerator" function to perform horizontal flipping, rotation, scaling, width and height shifting, and shearing. These augmentation techniques created a more diverse dataset, helping to prevent overfitting and improving the model's generalizability to new faces.

The investigators developed a binary classification model to identify delirium using a CNN with a pretrained backbone. The VGG16 model, based on deep learning, was adopted, leveraging transfer learning from VGGFace2, which possesses pre-existing facial feature recognition capabilities. Transfer learning allowed us to utilize prior knowledge to detect features more quickly, accurately, and with lower computational cost. The VGGFace2 model was employed for training.

Model performance was evaluated through internal validation at Beijing Tiantan Hospital and external validation at Guiyang Second People's Hospital, with metrics including accuracy, sensitivity, specificity, and F1 score. Additionally, to address the "black box" issue of machine learning, occlusion heatmap techniques were used to identify the most critical facial regions for delirium assessment, with the results visualized on a virtual face.

This model aims to support precise and efficient identification of delirium in neurocritical care units.

03

Conditions studied

  • Delirium
  • Artificial Intelligence (AI)

Browse trials for

Keywords

  • Delirium
  • Artificial Intelligence (AI)
  • neurocritical care units
  • Facial recognition
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study selects neurocritical patients as the population and collects facial expression data from both delirium and non-delirium patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Neurocritical patients admitted to the ICU, including postoperative neurosurgical patients, stroke patients, and those receiving ICU care due to other neurological conditions.
  2. Age over 18 years.
  3. Signed .

Exclusion criteria

Exclusion Criteria:

  1. Age under 18 years.
  2. Persistent coma (GCS ≤ 8) within 7 days pre- and post-surgery, making delirium assessment impossible.
  3. Did not survive more than 24 hours in the ICU.
  4. Patients with facial paralysis, post-traumatic facial disfigurement, or other conditions that could significantly affect facial recognition.
  5. Exclusion of patients with severe dementia, Parkinson's disease, depression, or other conditions that might impact facial emotional expressions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Neurocritical non-delirium patients

    For neurocritical non-delirium patients, the investigators record facial expression videos, which are used during model development to compare with the facial expressions of delirium patients.

  • Neurocritical delirium patients

    The investigators record facial expression videos of neurocritical delirium patients and perform frame sampling on the videos to analyze and extract the facial expression features specific to delirium. Based on this analysis, the investigators develop a model for delirium recognition in neurocritical patients.

06

What researchers measure

Primary outcomes

  1. Accuracy of the delirium prediction model

    The accuracy of the delirium prediction model will be calculated as the proportion of correct predictions among total predictions.

    Time frame: Through study completion, an average of 1 year

  2. Sensitivity of the delirium prediction model

    Sensitivity (true positive rate) will be assessed as the proportion of actual delirium cases correctly identified by the model.

    Time frame: Through study completion, an average of 1 year

  3. Specificity of the delirium prediction model

    Specificity (true negative rate) will be calculated as the proportion of non-delirium cases correctly identified by the model.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. F1 Score of the delirium prediction model

    The F1 score, the harmonic mean of precision and recall, will be used to evaluate the balance between sensitivity and specificity.

    Time frame: Through study completion, an average of 1 year

  2. AUC of the facial feature curve for delirium patients

    The area under the curve (AUC) of the receiver operating characteristic (ROC) curve derived from facial features will be used to assess the discriminatory performance of the model.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Heintz TA, Badathala A, Wooten A, Cu CW, Wallace A, Pham B, Wallace AW, Cobert J. Preliminary Development and Validation of Automated Nociception Recognition Using Computer Vision in Perioperative Patients. Anesthesiology. 2025 Apr 1;142(4):726-737. doi: 10.1097/ALN.0000000000005370. Epub 2025 Jan 13. PubMed 39804295 ↗
  • Atee M, Hoti K, Parsons R, Hughes JD. A novel pain assessment tool incorporating automated facial analysis: interrater reliability in advanced dementia. Clin Interv Aging. 2018 Jul 16;13:1245-1258. doi: 10.2147/CIA.S168024. eCollection 2018. PubMed 30038491 ↗
  • Goldberg TE, Chen C, Wang Y, Jung E, Swanson A, Ing C, Garcia PS, Whittington RA, Moitra V. Association of Delirium With Long-term Cognitive Decline: A Meta-analysis. JAMA Neurol. 2020 Nov 1;77(11):1373-1381. doi: 10.1001/jamaneurol.2020.2273. PubMed 32658246 ↗
  • Aldecoa C, Bettelli G, Bilotta F, Sanders RD, Audisio R, Borozdina A, Cherubini A, Jones C, Kehlet H, MacLullich A, Radtke F, Riese F, Slooter AJ, Veyckemans F, Kramer S, Neuner B, Weiss B, Spies CD. European Society of Anaesthesiology evidence-based and consensus-based guideline on postoperative delirium. Eur J Anaesthesiol. 2017 Apr;34(4):192-214. doi: 10.1097/EJA.0000000000000594. PubMed 28187050 ↗
  • Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, Speroff T, Gautam S, Bernard GR, Inouye SK. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 Jul;29(7):1370-9. doi: 10.1097/00003246-200107000-00012. PubMed 11445689 ↗
  • Ahmed A, Garcia-Agundez A, Petrovic I, Radaei F, Fife J, Zhou J, Karas H, Moody S, Drake J, Jones RN, Eickhoff C, Reznik ME. Delirium detection using wearable sensors and machine learning in patients with intracerebral hemorrhage. Front Neurol. 2023 Jun 9;14:1135472. doi: 10.3389/fneur.2023.1135472. eCollection 2023. PubMed 37360342 ↗
  • Al-Hindawi A, Vizcaychipi M, Demiris Y. A Dual-Camera Eye-Tracking Platform for Rapid Real-Time Diagnosis of Acute Delirium: A Pilot Study. IEEE J Transl Eng Health Med. 2024 May 7;12:488-498. doi: 10.1109/JTEHM.2024.3397737. eCollection 2024. PubMed 39050621 ↗
  • Oh J, Cho D, Park J, Na SH, Kim J, Heo J, Shin CS, Kim JJ, Park JY, Lee B. Prediction and early detection of delirium in the intensive care unit by using heart rate variability and machine learning. Physiol Meas. 2018 Mar 27;39(3):035004. doi: 10.1088/1361-6579/aaab07. PubMed 29376502 ↗
  • Eeles E, Tronstad O, Teodorczuk A, Flaws D, Fraser JF, Dissanayaka N. Face and content validity of a mobile delirium screening tool adapted for use in the medical setting (eDIS-MED): Welcome to the machine. Australas J Ageing. 2024 Jun;43(2):415-419. doi: 10.1111/ajag.13288. Epub 2024 Feb 28. PubMed 38415380 ↗
  • Nejati V, Khorrami AS, Fonoudi M. Neuromodulation of facial emotion recognition in health and disease: A systematic review. Neurophysiol Clin. 2022 Jun;52(3):183-201. doi: 10.1016/j.neucli.2022.03.005. Epub 2022 Apr 12. PubMed 35428551 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This study involves collecting facial information of patients, which pertains to their privacy. To protect participants' confidentiality, all data will be uniformly destroyed after the study is completed. The investigators will not share or disclose patients' information to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.

Of 177 non-industry observational studies under Delirium, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 4 months is below that.

Counting every sponsor, half of 179 studies reached it within 20 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 22, 2025
StartEst.
Aug 30, 2025
Primary completionEst.
Dec 30, 2025
CompletionEst.
Jan 30, 2026
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07136207
Collaborators
Affiliated Jinyang Hospital of Guizhou Medical University, The Affiliated Hospital Of Guizhou Medical University
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 30, 2025 (estimated)
Primary completion
Dec 30, 2025 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Aug 22, 2025

Study contacts

Huang Huawei, Doctoral degree
Contact
huanghw0403@163.com
+8613599058877 ext. 59978000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion